Search
Displaying 751–760 of 894 results for “vision connection”
-
Atsena to Launch Part B of Phase 1/2 Clinical Trial for XLRS Gene Therapy
Research NewsThe Foundation is a founding investor in Atsena.
-
Research News
The company is also planning to conduct the clinical trial at sites in the EU.
-
Staying True to Music, Family, and Advocacy
Beacon StoriesMusic duo Andrew & Polly have earned a GRAMMY nomination for their children’s album “Ahhhhh!” while also championing disability awareness and inclusivity. Andrew’s experience with Stargardt disease fuels their advocacy, inspiring others through their music, podcast, and dedication to research and community support.
-
Research News
Strengthening research in retinal disease with record-breaking $19.8 million investment in innovative projects targeting vision loss worldwide.
-
Eye on the Cure Podcast | Episode 75: Sharon King
Eye on the CureSharon King, co-founder and president of Taylor’s Tale, talks to host Ben Shaberman about her family’s journey when her daughter Taylor was diagnosed with Batten disease.
-
AAVantgarde Bio’s Dual-Vector USH1B Gene Therapy Moves into Phase 1/2 Clinical Trial
Research NewsThe trial is the first ever for a dual AAV gene therapy delivered to the retina.
-
Research News
The Phase 3 trial is expected to begin in Q1 2025
-
Lead With Luna: Meredyth’s Journey With Her Guide Dog
Beacon StoriesIn honor of National Dog Day, we’re celebrating the work of guide dogs and raising awareness about the importance of guide dog services by sharing Meredyth’s story. Her guide dog, Luna, has greatly improved her independence and quality of life, showcasing the significant benefits of guide dog services for those who are blind or have low vision.
-
A Para Triathlete's Journey With Stargardt
Beacon StoriesThis exclusive Beacon Story podcast features WROC’s Adam Chodak and professional Para triathlete Deb Chucoski as they discuss living with Stargardt disease and the amazing achievements of those who refuse to let it define them.
-
Genentech to Re-Introduce Susvimo for Wet AMD
Research NewsFDA-approved in 2021, the tiny implantable capsule provides sustained delivery of treatment, but was recalled in 2022.
_2023.jpg)
.png)
